Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Accumulated Expenses (2016 - 2025)

Iradimed (IRMD) has disclosed Accumulated Expenses for 13 consecutive years, with $4.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses rose 3344.22% to $4.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.1 million, a 3344.22% increase, with the full-year FY2024 number at $118269.0, up 0.69% from a year prior.
  • Accumulated Expenses was $4.1 million for Q3 2025 at Iradimed, up from $121221.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $4.1 million in Q3 2025 to a low of $94030.0 in Q4 2022.
  • A 5-year average of $776925.9 and a median of $117463.0 in 2023 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: crashed 94.87% in 2024, then soared 3344.22% in 2025.
  • Iradimed's Accumulated Expenses stood at $108880.0 in 2021, then dropped by 13.64% to $94030.0 in 2022, then rose by 24.92% to $117463.0 in 2023, then increased by 0.69% to $118269.0 in 2024, then surged by 3342.3% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Accumulated Expenses are $4.1 million (Q3 2025), $121221.0 (Q2 2025), and $2.3 million (Q1 2025).